Xcenda Expertise Showcased at AMCP Annual Meeting in Boston
April 14, 2018
Xcenda Continues Excellence in Innovative Research
Join us at the AMCP Annual Expo in Boston from April 24 through April 26.
We are proud to "sweep the podium" and present the following award-winning research at AMCP. Meet our managed markets and global HEOR experts at booth #321.
|Payers’ experiences regarding proactive dissemination of health care economic information (HCEI) prior to and after passage of the 21st Century Cures Act||Ena Begovic, Amy Duhig, Jay Jackson, Stewart Kauffman, Janet Hughes, Matt Sarnes, Soumi Saha|
|Payers’ perceptions of the importance and usefulness of preapproval information exchange (PIE) of healthcare economic information prior to product approval||Ena Begovic, Amy Duhig, Jay Jackson, Stewart Kauffman, Janet Hughes, Matt Sarnes, Soumi Saha|
|Payer Evaluation of Organizational Management Approaches to Limit Opioid Abuse and Overdose Deaths in the United States||Andrew Gaiser, Maher Abdel-Sattar, Nisreen Shamseddine, Scott Shields|
|Payer Perspective on the Academy of Managed Care Pharmacy (AMCP) Format Version 4.0 (v4.0) Pre-approval Dossier in a Managed Care Network||Lorie Mody, Kim Boswell, Steve Ren, Stewart Kaufman, Janet Hughes, and Evelyn Sarnes|
|The Economic Impact of Emflaza for the Treatment of Duchenne Muscular Dystrophy||Rashad Carlton, Tim Regan|
AMCP 2018 Boston Speaker Highlights
Wednesday, April 25, 2018 | 8:30 AM - 9:45 AM | Room: 258 ABC
Best Practices to Implementing Proactive Communications Between Manufacturers and Payers
Moderator: Soumi Saha, PharmD, JD
The recent enactment of the 21st Century Cures Act, and specifically Section 3037 (Cures 3037), modernized provisions of the Food and Drug Administration Modernization Act of 1997, Section 114 (FDAMA 114), which governs proactive dissemination of health care economic information (HCEI) by manufacturers to payers post-approval. This session will briefly review the evolution of payer and manufacturer communications, and the impact on managed care pharmacy, manufacturers and evidence generators. The panelists will also discuss best practices for operationalizing proactive communications and additional areas for improvement in the future.
Tuesday, April 24, 2018 | 10:00 AM - 11:00 AM | Room:157 AB
Importance of Patient Reported Outcomes (PROs)
Faculty: Somali Burgess, PhD
What are patient reported outcomes (PROs), and how are they important to managed care pharmacy? This is the perfect session to build your foundational knowledge on how PROs support better care for patients. PROs use patient experiences with medications and treatments to provide data and feedback, which allows clinicians and patients to choose better interventions to help drive better outcomes and value. While the health care system strives to better use PROs, this session will also discuss challenges and barriers with the implementation of PROs in managed care pharmacy, as well as opportunities to help overcome those barriers and improve patient care.
Wednesday, April 25, 2018 | 6:00 PM - 8:00 PM
Town Hall: Redefining Value Propositions and Managed Care Considerations in Multiple Myeloma
Dr. Blazer will participate as a panelist in this town hall-style open forum to share and discuss the challenges when faced with optimizing outcomes for patients with multiple myeloma (MM) across several lines of therapy. Join this panel in dialogue on risk-stratified approaches, including how to integrate the latest clinical evidence, guidelines, and response monitoring into re-treatment decisions while containing lifetime treatment costs. Interpret the latest real-world data on MM treatment usage, analyze the long-term impact on patients and systems, and consider the value-based implications of sequencing combination regimens through the lens of managed care professionals.